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Purpose: To describe the phenotype of a novel Wolframin (WFS1) mutation in a family with autosomal dominant optic
neuropathy and deafness. The study is designed as a retrospective observational case series.
Methods: Seven members of a Dutch family underwent ophthalmological, otological, and genetical examinations in one
institution. Fasting serum glucose was assessed in the affected family members.
Results: All affected individuals showed loss of neuroretinal rim of the optic nerve at fundoscopy with enlarged blind
spots at perimetry. They showed a red-green color vision defect at color vision tests and deviations at visually evoked
response tests. The audiograms of the affected individuals showed hearing loss and were relatively flat. The unaffected
individuals showed no visual deviations or hearing impairment. The affected family members had no glucose intolerance.
Leber hereditary optic neuropathy (LHON) mitochondrial mutations and mutations in the Optic atrophy-1 gene (OPA1)
were excluded. In the affected individuals, a novel missense mutation c.2508G>C (p.Lys836Asn) in exon 8 of WFS1 was
identified.
Conclusions: This study describes the phenotype of a family with autosomal dominant optic neuropathy and hearing
impairment associated with a novel missense mutation in WFS1.
Hereditary optic neuropathy (HON) is a disease entity
characterized by symmetric, bilateral, central visual loss with
deviations of the papillomacular nerve fiber bundle resulting
in cupping of the disk and in central or cecocentral scotomas
and generalized constriction of the visual fields. In later
stages, visual loss becomes severe, usually worse than 20/200
[1]. HON is seen in isolated autosomal dominant optic
neuropathy, in Leber hereditary optic neuropathy (LHON;
OMIM 535000), in Wolfram Syndrome (OMIM 222300), and
in diseases with primarily neurologic or systemic
manifestations such as hereditary ataxias, hereditary
polyneuropathies, hereditary spastic paraplegias, hereditary
muscular dystrophies, and storage diseases [2].
The combination of autosomal dominant optic
neuropathy and deafness has been reported in families and in
isolated cases with a heterozygous missense mutation in Optic
atrophy-1 gene (OPA1; OMIM 605290) [3–6]. Eiberg et al.
[7] described a Danish family who had autosomal dominant
optic neuropathy and deafness caused by a mutation in the
Wolframin (WFS1) gene. WFS1, on chromosome 4p16.3,
contains eight exons. Mutations in this gene are reported to be
responsible for Wolfram Syndrome, Deafness Autosomal
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dominant type 6/14 (DFNA6/14; OMIM 600965, a low-
frequency sensorineural hearing loss that is inherited in an
autosomal dominant manner), psychiatric disorders, and
diabetes mellitus (OMIM 606201). After examination of the
family with autosomal dominant optic neuropathy and
deafness, Eiberg et al. [7] concluded that the patients also had
impaired glucose tolerance. Valéro described a French family
with the same missense mutation [8]. There were only two
affected individuals: the proband and his mother suffered
diabetes mellitus with congenital hearing loss. At the age of
60 the mother was diagnosed with optic atrophy. The present
report describes the phenotype of a third family with
autosomal dominant optic neuropathy and deafness that is
associated with a novel missense mutation in WFS1.
METHODS
The proband, a 57-year-old man, was referred to our tertiary
referral hospital for progressive hearing loss, which coexisted
with optic neuropathy. The question was raised whether he
was a good candidate for cochlear implantation. Medical
history showed that both his mother and brother also had optic
neuropathy and hearing loss. Figure 1 shows the pedigree of
this family. Informed consent was obtained from both the
proband and his family to participate in this study. The
research adhered to the tenets of the Declaration of Helsinki
and was approved by the Institutional Review Board
(Commissie Mensgebonden Onderzoek), Radboud
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University Nijmegen Medical Centre, Nijmegen, The
Netherlands.
All family members were examined in our outpatient
clinic and medical history was taken. For all family members
except patient II:2, the ophthalmological examinations
included best corrected visual acuity measurements, slit-lamp
microscopy and ophthalmoscopy. Goldmann perimetry was
performed to evaluate visual field size. A morphometric
analysis of the optic disc was performed using the Heidelberg
Retina Tomograph II (HRT; Heidelberg Engineering,
Heidelberg, Germany) [9]. Color vision was assessed with the
Hardy-Rand-Ritter (HRR) pseudoisochromatic plates, the
Lanthony new color test, the Neitz anomaloscope (Neitz,
Tokyo, Japan), and the standard pseudoisochromatic plates
test. In addition, visually evoked potentials (VEP; Roland
Consult, Brandenburg, Germany) were evaluated. Patient II:
2 only underwent standard ocular examinations. All
individuals underwent pure-tone audiometry and speech
audiometry. Otoscopy was performed on all family members
to rule out middle ear pathology. As part of a preoperative
selection procedure for cochlear implantation, the proband
also underwent electronystagmography, computed
tomography (CT), and auditory steady-state response (ASSR)
testing.
The affected family members underwent fasting serum
testing to exclude diabetes mellitus (serum specific insulin,
serum C-peptide and HbA1C were analyzed in the proband
and plasma glucose was analyzed in all affected individuals).
Blood samples of all living individuals were collected in
EDTA tubes and kept at room temperature. DNA was isolated
within five days after withdrawal on a Chemagen MSM1
Figure 1. The p.Lys836Asn mutation in the studied family with
autosomal dominant optic neuropathy and hearing impairment. In
the pedigree the individual number, the age of the individual, and the
WFS1 genotypes are depicted. The affected woman and her two sons
suffer optic neuropathy and hearing impairment and carry the c.
2508G>C WFS1 mutation. Abbreviations: c.2508G>C WFS1
mutation (C); wildtype allele (wt).
TABLE 1. WFS1 PRIMERS.
Exon Forward primer (5′-3′) Reverse primer (5′-3′)
2 TGTCTCCAGCAGACACTAAG GGGTGGCTGAACCCCGTTC
3 GAAGACCCTCATGCCTTGTC ATCTCAGGCACCGACACTTC
4 GGAGAATCTGGAGGCTGACT ACAAGCTGCTCAACCCTCCA
5 AGAGTGGCACCGAAACCA TCCTGTGGGAAGACCCAG
6 AACAGTGCGCCAGTTTCTG GAGGCACGGGTGAGATAGG
7 CCCATTGCTCTGTGTGAGG GAAGGTGCCCTGCCTGAG
8–1 AGAGGCAGGGTGGTCAGAG GAGAGCAGGAAATGGGCATA
8–2 AGAACTTCCGCACCCTCAC AGGTAGGGCACAAGGTAGCA
8–3 TATCTCTTCTTCCGCATGGC TACTGCTGCCAGGTCAGTGT
8–4 CAAGCTCATCCTGGTGTGG GTGACGTCGTCCTCCTCG
8–5 CCCTGCCACATCAAGAAGTT GGTCTCTGCAGCCACAGTCT
The table shows the forward and reverse primers used for PCR amplification of the coding exons of the WFS1 gene. Exons 2
to 7 were amplified as single fragments, whereas the larger exon 8 was amplified in 5 overlapping fragments. PCR was performed
using AmpliTaq Gold 360 Master mix (Applied Biosystems, Foster City, CA) with 50 ng genomic DNA and 10 pmol of each
primer in a total volume of 25 µl. PCR reaction conditions for all fragments were: 95 °C for 10 min; then 35 cycles of 95 °C
for 30s, 60 °C for 1 min and 72 °C for 30s, followed by 7 min at 72 °C.
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platform using the Chemagic DNA blood 10k kit (Chemagen,
Baesweiler, Germany). Mutation analysis of WFS1 was
performed by direct sequencing of the entire coding region
Figure 2. Phenotypic characterization of two members of a Dutch
family. A: The upper portion presents the visual field printouts of the
Goldmann perimetry (GP) test, and the lower part shows screenshots
from Heidelberg Retina Tomograph II (HRT). The right and left
column correspond to the right and left eye of individual IV:2,
respectively. The small temporal black area in the GP corresponds
to the physiologic blind spot. HRT scans demonstrate a physiologic
optic disc cupping measure (red areas) and a physiologic thinned
neuroretinal rim (blue-green area) of the optic disc. B: GP and HRT
results for III:3 are shown. The large dark areas in the GP correspond
to the enlarged blind spot due to optic neuropathy. HRT scans
demonstrate increased optic disc cupping measure (red areas) and a
thinned neuroretinal rim (blue-green area) of the optic disc.
(exon 2 to 8). The coding exons and the flanking intronic
sequences were PCR amplified and subsequently sequenced
on a 3730 automated sequencer using Dye terminator
chemistry (Applied Biosystems, Foster City, CA). For primer
information and PCR conditions see Table 1. In addition,
OPA1 and three known LHON mutations (mtDNA positions
m.11778, m.3460, and m.14484) were screened by a
combination of dHPLC (Transgenomic, Inc., Omaha, NE) and
direct sequencing analysis.
RESULTS
Medical history: From the pedigree in Figure 1, it can be
concluded that the disease has an autosomal dominant or
mitochondrial inheritance pattern. Neither the maternal
grandparents nor the uncle of the proband had hearing
impairment. All affected individuals had no symptoms
additional to progressive sensorineural hearing impairment
and optic atrophy. No other Wolfram syndrome-related
symptoms (diabetes mellitus, diabetes insipidus, renal or
psychiatric problems) were mentioned during each
participant’s history and physical examination.
Ophthalmological results: The results of the
ophthalmological examinations are shown in Table 2 and
Figure 2. It should be noted that not all the family members
were examined ophthalmologically and that the unaffected
individuals that were examined ophthalmologically were of a
younger generation than the affected individuals. All affected
individuals had an enlarged blind spot at Goldmann perimetry,
loss of neuroretinal rim on HRT, and a deviating VEP. They
also showed an indication of protan and deutan axes (i.e., a
red-green defect) at color vision testing. The unaffected
individuals did not have an enlarged blind spot at Goldmann
perimetry, loss of neuroretinal rim on HRT, nor a deviating
VEP.
Hearing results: The results of otological and audiological
examinations are shown in Table 3. Otoscopy showed no
abnormalities in all patients. Hearing was normal in both
children (IV:1 and IV:2) of the proband and also normal (for
his age) in the only living uncle (II:3) of the proband. For all
affected individuals, the first available and last-visit pure-tone
audiograms are shown in Figure 3, upper panel. They
demonstrate a relatively flat-type of hearing loss at last visit.
Remarkably, hearing in both the proband and his mother is so
diminished that they hardly have any speech recognition.
Individual III:3, the youngest of these three affected
participants, still has relatively normal maximum speech
recognition scores. His first available pure-tone audiogram
demonstrated a typical low-frequency sensorineural hearing
loss. No progression of hearing loss could be deduced from
the pure-tone audiograms of study participants II:2 and III:2.
The proband had normal vestibular function. CT scan of
the temporal bone showed no anatomic abnormalities. Central
causes of sensorineural hearing loss were excluded by ASSR
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testing, which revealed normal function of the auditory nerve.
The proband underwent successful right ear cochlear
implantation with a 22-electrode implant (Cochlear; Nucleus
Freedom, Sidney, Australia). Seven months after
implantation, he was found to have 83% speech recognition
at 70 dB sound pressure level (SPL). Prior to implantation,
aided thresholds with a conventional aid on the right were
tested: no speech recognition was found at 70 dB SPL and the
maximum speech recognition of about 20% was found at
80 dB SPL.
Genetic results: Screening of mtDNA positions m.11778, m.
3460 and m.14484 demonstrated that the three most frequent
LHON mutations were not present. Screening of WFS1 and
OPA1 revealed no mutations in all coding regions of OPA1.
In exon 8 of WFS1, a heterozygous mutation was identified in
all three affected patients. This variant was not detected in the
unaffected family members. At position 2508, a substitution
of a cytosine for a guanine (c.2508G>C) leads to the amino
acid substitution p.Lys836Asn. Based on the medical history
and clinical information available, we assume that this is a de
novo mutation. Figure 4 shows the normal and mutated
sequences. We believe this variant to be pathogenic because
the mutated lysine is evolutionarily highly conserved (Figure
5), is located in a conserved region of the protein, and
cosegregates with the disease in this family. In addition, this
variant has never been identified in our laboratory (so far we
analyzed the WFS1 sequence in 200 European patient
chromosomes).
Exclusion of diabetes mellitus: Diabetes mellitus was
excluded in the affected individuals by assessing fasting
serum glucose (all within the reference value 4.0–5.6 mmol/
l) and HbA1C (all within the reference value 4.2%–6.3%). In
the proband, insulin (9 mE/l, reference value 8–20) and C-
peptide (0.62 mmol/l, reference value 0.17–1) were assessed
as well, and found to be in the normal range.
TABLE 2. OPHTHALMOLOGICAL EXAMINATION RESULTS
Patient
Age
(Y) Sex
Mutation
reported in
WFS1
AoO
(Y) Eye BCVA Media Papilla Visual field VEP
Color
vision HRT
II:2 85 F + 30 RE 0.1 Clear Optic
disc
atrophy
Na Na Na Na
     LE 0.05 Clear Optic
disc
atrophy
Na Na Na Na
III:2 57 M + 11 RE 0.1 Clear Optic
disc
atrophy
Enlarged blind
spot
Delayed
response
Marked
protan and
deutan
axes
Outside
normal
limits
     LE 0.2 Clear Optic
disc
atrophy
Enlarged blind
spot
Delayed
response
Marked
protan and
deutan
axes
Outside
normal
limits
III:3 50 M + 10 RE 0.2 Clear Optic
disc
atrophy
Enlarged blind
spot
Delayed
response
Marked
protan and
deutan
axes
Outside
normal
limits
     LE 0.4 Clear Optic
disc
Atrophy
Enlarged blind
spot
Delayed
response
Marked
protan and
deutan
axes
Outside
normal
limits
IV:1 26 F - 11 RE 1.6 Clear Normal No significant
alterations
Intact Normal Normal
     LE 1.2 Clear Normal No significant
alterations
Intact Normal Normal
IV:2 23 M - 11 RE 1.6 Clear Normal No significant
alterations
Intact Normal Normal
     LE 1.6 Clear Normal No significant
alterations
Intact Normal Normal
For the patients the age in years (Y) is shown as well as whether they carry the WFS1 mutation and their age of onset of
ophthalmological complaints (AoO). The results of ophthalmological examination tests are depicted for each eye separately.
The mutation carrying individuals all have optic disc atrophy and decreased results of Snellen test for best corrected visual acuity
(BCVA). The results of the tests for visual field, visually evoked potentials (VEP), color vision and Heidelberg Retinal
Tomography (HRT) were impaired for the affected individuals. The not affected individuals showed normal results for these
tests. Abbreviations: female (F); male (M); right eye (RE); left eye (LE); not available (Na).
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DISCUSSION
In this article we report a novel missense mutation
(p.Lys836Asn) in exon 8 of WFS1 that is associated with
autosomal dominant optic neuropathy and deafness. The
disease shows 100% segregation with the mutation. The three
affected individuals did not have diabetes mellitus or any other
symptoms. Since there was no autosomal recessive
inheritance, they did not present with Wolfram syndrome
spectrum. They also did not have DFNA6/14, the
nonsyndromic autosomal dominant low frequency
sensorineural hearing loss that is caused by WFS1 mutations.
The affected participants did show more severe sensorineural
hearing loss with involvement of all frequencies, and they did
have optic atrophy.
Hereditary optic neuropathy: HON is a clinically and
genetically heterogeneous condition. Isolated autosomal
dominant optic neuropathy is caused by four genes: OPA1,
OPA3, OPA4, and OPA5. OPA1 (OMIM 165500) is the most
frequently encountered type of isolated autosomal dominant
optic neuropathy. Symptoms usually manifest in the first
decade of life, and, in most cases, visual impairment develops
gradually over many years. The reduction in visual acuity
tends to be mild or moderate [10,11]. Visual field defects
mainly involve the central portion of the field and include
cecocentral scotomas, paracentral defects, and
pseudobitemporal defects. Neuroretinal rim pallor in
autosomal dominant optic neuropathy is most pronounced
temporally, but usually involves the entire optic disc [10].
Optic neuropathy is also a sequela of LHON. LHON is
the result of maternal mitochondrial DNA mutations. Visual
loss usually begins painlessly and centrally in one eye, and the
second eye is affected weeks to months later with an acute or
subacute course. However, the duration of progression of
visual loss in each eye varies and may be difficult to document
accurately. Eventually, optic atrophy bundle supervenes [2].
Optic neuropathy is also one of the main symptoms in
Wolfram syndrome. Caused by mutations in WFS1 on
chromosome 4p16.3, Wolfram syndrome is an autosomal
recessive neurodegenerative syndrome [12]. The minimal
criteria for diagnosis are diabetes mellitus and optic atrophy
[1]. Sensorineural hearing loss is often an additional finding.
Autosomal dominant optic neuropathy and deafness: The
affected individuals of the described family have severe optic
nerve damage as well as sensorineural hearing loss that is
inherited in an autosomal dominant way. In 1977, Deutman
presented a family with autosomal dominant optic neuropathy
and deafness similar to our family: the affected individuals
had sensorineural hearing impairment and optic atrophy but
no other symptoms. All affected individuals had hearing loss
with a relatively flat audiogram, an enlarged blind spot at
Goldmann perimetry, deutanomaly, and a deviating VER
[13]. There was no information available on the genetic
background of this family.
Autosomal dominant optic neuropathy and deafness has
also been reported in several families and in isolated cases
with a heterozygous missense mutation (p.Arg445His or
p.Gly439Val) in OPA1 [3–5,14]. In our family, the
presentation of the optic atrophy and the bilateral progressive
sensorineural hearing loss is similar to the presentation of the
families with autosomal dominant optic neuropathy and
deafness and a mutation in OPA1. However, OPA1 mutations
were excluded by sequencing analysis. In addition, the
OPA1 mutations seem to cause a broader phenotype with
ptosis, ophthalmoplegia, ataxia, axonal sensory-motor
polyneuropathy, and mitochondrial myopathy [5,14,15].
Another OPA1 mutation (p.Tyr582Cys) is responsible for
TABLE 3. OTOLOGICAL AND AUDIOLOGICAL EXAMINATION RESULTS
Patient
Age
(Y) Sex
Mutation
reported in
WFS1
AoO
(Y) Otoscopy
FI RE/LE
(dB HL)
MSRS
RE/LE
(%) ENG ASSR
CT temporal
bone
II:2 85 F + 9 Normal 98/100 3/0 Na Na Na
II:3 75 M - Normal 10/12               Na              Na Na Na
III:1 57 F - Normal 22/18 100/10
0
Na Na Na
III:2 57 M + 8 Normal 90/97 15/0 Normal Conform pure
tone audiogram
No anatomic
abnormalities
III:3 51 M + 14 Normal 58/60 93/90 Na Na Na
IV:1 26 F - Normal 5/7                 Na              Na Na Na
IV:2 23 M - Normal 18/20 100/100 Na Na Na
For the patients the age in years (Y) is shown as well as whether they carry the WFS1 mutation and their age of onset of
audiological complaints (AoO). The results of the audiological examination tests are depicted for each ear separately. The ears
of the mutation carrying individuals have an increased Fletcher Index (FI; mean threshold for 0.5, 1, and 2 kHz) and a decreased
maximum speech recognition score (MSRS). Abbreviations: female (F); male (M); right ear (RE); left ear (LE); decibel hearing
loss (dB HL); electronystagmography (ENG); auditory steady-state response (ASSR); computed tomography (CT); not available
(Na).
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progressive hearing loss that necessitated cochlear
implantation, macrocytic anemia, and hypogonadism [16].
Interestingly, the patient of this case had progressive external
ophthalmoplegia and central vision loss. Because no optic
pallor was seen on fundoscopy, it was believed the patient’s
vision loss was not caused by optic atrophy.
The combination of hearing loss and LHON has not been
ascribed to a single mutation so far [17]. However, Hofmann
and coworkers [18] proposed that LHON mutations represent
a susceptibility factor for Wolfram syndrome which, by
interaction with further exogeneous or genetic factors, might
increase the risk for disease. In our family, the main LHON
mutations were excluded by sequencing analysis. The
phenotype of LHON mutations is characterized by an acute
or subacute loss of visual acuity with changes of the optic disc.
None of the affected family members suffered such a period.
Wolframin: WFS1 encodes for wolframin, a protein known to
contain nine predicted transmembrane domains. So far, about
110 mutations in WFS1 are believed to cause the Wolfram
syndrome [19–23]. Eiberg [7] and Valéro [8] reported two
families who had a WFS1 missense mutation (p.Gln864Lys)
in the same conserved region as the mutation that we found.
This mutation caused an autosomal dominant clinical triad:
congenital hearing impairment, diabetes mellitus, and optic
atrophy. In the study by Valéro, however, the proband (thus
far) had no optic atrophy [8]. Mutations in WFS1 are also
responsible for other conditions such as psychiatric disorders
and diabetes mellitus (Lesperance laboratory database). The
pleiotropy of this disorder can possibly be explained by
alternative splicing: missense mutations would occur in
regions that are spliced out in specific organs. Challenging
WFS1 expression studies of these organs would be needed to
prove or reject this hypothesis.
Figure 3. Audiograms of individuals
with the p.Lys836Asn mutation in the
WFS1 gene. The mean pure-tone
audiograms of right and left ear in
affected persons II:2 (age 60 and 85
years), III:2 (age 52 and 57 years) and
III:3 (age 37 and 51 years) are depicted
in panel A. Dotted lines and upward
triangular symbols indicate first
available and straight lines, and
downward triangular symbols indicate
last-visit mean audiogram. The mean
age-related typical audiograms for
DFNA6/14, adapted and modified from
Pennings and coworkers [29], are
depicted in panel B.
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To date, 26 WFS1 mutations have been reported to cause
DFNA6/14 [21–24], an unusual type of hearing loss that
affects frequencies at 2,000 Hz and below [25–27]. In general,
hearing loss in DFNA6/14 is not progressive, however, some
families were reported to have progressive hearing loss that
could be attributed to presbycusis [28,29]. Because high
frequency hearing is generally preserved, DFNA6/14 patients
retain excellent understanding of speech, although
presbycusis may cause high-frequency hearing loss later in
life. Consequently, DFNA6/14 in younger patients is often
asymptomatic, and many patients choose not to wear hearing
aids. This contrasts with the affected family members in the
current family who showed a flat-type of hearing loss with
poor speech recognition.
Due to a lack of previous audiograms, it was difficult to
evaluate progression of hearing loss in II:2 and III:2. It should
however be noted that the first available audiograms of II:2
were made at the age of 60 years and that the first available
audiograms of III:2 were made at the age of 60 years.
Progression of their hearing loss may have occurred before
these ages. Interestingly, the first pure-tone audiogram of III:
3, done at the age of 38 years, shows a more pronounced loss
at the lower frequencies, resembling the hearing loss
characteristic of DFNA6/14 (see Figure 3, upper and lower
panel).
Individual III:3 typically had low-frequency
sensorineural hearing loss that resembled DFNA6/14 at the
age of 38 years. In the following years, he experienced
progression of his hearing loss at 8 kHz (40 dB) that appears
to be bigger than the mean deterioration (approximately 1 dB/
year) that was reported for this frequency based on analyses
in several families with DFNA6/14 [28]. The hearing
impairment in his brother, III:2, and his mother, II:2, is too
profound for DFNA6/14. Thus it can be concluded that the
phenotype of this novel WFS1 mutation is more severe when
compared to DFNA6/14. Hearing appears to deteriorate more
progressively for the WFS1 mutation and these patients also
develop optic neuropathy.
Pathogenesis of optic neuropathy due to WFS1 mutations:
The distribution of wolframin in the mammalian visual
system, and the pathogenesis of optic atrophy due to mutations
in WFS1 remain unclear. Expression studies, however, have
assessed the presence of wolframin in retinal ganglion cells
and optic nerve glia cells of the cynomolgus monkey [30]. In
rodents, the presence of mRNA and wolframin have been
examined in the retina (amacrine cells, Müller cells,
photoreceptors, horizontal cells, bipolar cells and retinal
ganglion cells), in the optic nerve (particularly in astrocytes),
in the optic tract, and in the brain (the superior colliculus, the
dorsomedial part of the suprachiasmatic nucleus and layer II
of the primary and secondary visual cortices) [31]. Kawano
and coworkers hypothesized that mutant wolframin may
contribute to the dysfunction of wolframin-expressing
neurons as well as glial cells, which, in turn, may lead to optic
neuropathy [31].
Pathogenesis of deafness due to WFS1 mutations: The
function of wolframin in the inner ear and the mechanisms by
which missense mutations cause hearing loss have not been
extensively explored [32]. The expression of wolframin has
been localized to the mouse cochlea at different
developmental stages and is widely distributed in different
cochlear cell types, including inner and outer hair cells, a
variety of supporting cells, and cells of the lateral wall, spiral
ganglion, and vestibule [33]. A similarity has been observed
between wolframin expression and the presence of the
canalicular reticulum, a specialized form of endoplasmic
reticulum that is believed to be involved in transcellular ion
transport [34]. Thus, wolframin may be involved in regulation
of inner ear ion homeostasis as maintained by the canalicular
reticulum [33,34]. The majority of causative DFNA6/14
mutations have been identified in exon 8, which contains the
conserved C-terminal domain. This domain seems to have a
crucial function in the cochlea [22,33], and the p.Lys836Asn
mutation is also located in this domain. Because the proband
Figure 4. The p.Lys836Asn mutation in the WFS1 gene. The figure
shows results of the DNA sequence analysis of part of exon 8 of the
WFS1 gene. The upper chromatogram exhibits the wildtype sequence
whereas the lower chromatogram shows the sequence of an affected
family member. The arrowhead marks the nucleotide at position
2508. The results show that the patient heterozygous for a guanine
(G; yellow peak) to cytosine (C; blue peak) exchange at this position,
which translates into a lysine to asparagine amino acid substitution
at position 836 of the corresponding protein.
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of our study family highly benefits from his cochlear implant,
this suggests that indeed there is a deleterious effect of the
present WFS1 mutation in the cochlea without any
neurodegenerative symptoms that are so common in Wolfram
syndrome. It is still not clear why DFNA6/14 patients show a
stable low frequency hearing impairment with minor
progression and why the affected family members in our study
have such severe progression and profound hearing
impairment. Interestingly, in our study family with visual
impairment by optic neuropathy, there were no signs that the
hearing impairment is caused by auditory neuropathy.
According to the literature [35], most patients with Wolfram
syndrome do not have auditory neuropathy, but most have
sensorineural hearing loss caused by degeneration of the
organ of Corti. In addition, patients with missense mutations
in WFS1, causing DFNA6/14, also have sensorineural hearing
loss and no auditory neuropathy. Apparently, this specific
missense mutation in WFS1 has a different effect in the inner
ear than in the eye. Further studies are needed to elucidate the
underlying pathogenetic mechanism [36].
Conclusion: The results of our study suggest that
p.Lys836Asn is a novel mutation in WFS1 that is associated
with autosomal dominant optic neuropathy and finally a
severe to profound hearing loss with relatively flat
audiograms. The present phenotype is similar to the
phenotype caused by the only other reported WFS1 missense
mutation (p.Gln864Lys) that causes autosomal dominant
optic neuropathy and deafness. However, some of those
patients also have impaired glucose intolerance [7], and one
patient has no optic neuropathy [8]. It is also similar to the
phenotype of OPA1 mutations causing autosomal dominant
optic neuropathy and deafness, however, in general these
Figure 5. Evolutionarily conservation of the lysine residue at position
836 of the WFS1 protein. Evolutionarily conservation of the lysine
residue at position 836 of the WFS1 protein was assessed through
multiple alignment of WFS1 protein sequences derived from
different species. The arrowhead marks the lysine residue (K) at
position 836. The multiple sequence alignment shows that the lysine
is highly conserved in the different species which provides evidence
that this residue is important for proper protein functioning.
mutations cause a more extensive phenotype that includes
ptosis, ophthalmoplegia, ataxia, axonal sensory-motor
polyneuropathy, mitochondrial myopathy, macrocytic
anemia, and hypogonadism [6,14–16]. The symptoms in our
study family also clearly differ from the clinical presentation
of LHON, Wolfram syndrome, and DFNA6/14. On the basis
of this study we advise to perform extensive genetic testing of
at least WFS1 and OPA1 in cases of autosomal dominant optic
neuropathy and deafness.
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